HMGB1 and atherosclerosis: Because administration of anti-HMGB1-neutralizing antibody reduces atherosclerosis in mice (44) and a peptide that antagonizes B box cytokine activity prevents cancer progression (45, –, 47), blockade of HMGB1 could be an effective therapeutic strategy for treating these diseases.